Correlation among Hypoglycemia, Glycemic Variability, and C-Peptide Preservation after Alefacept Therapy in Patients with Type 1 Diabetes Mellitus: Analysis of Data from the Immune Tolerance Network T1DAL Trial

Clinical Therapeutics

Volumn 38, Issue 6, 2016, Pages 1327-1339

  Pinckney, Ashley ^a   Rigby, Mark R ^b,e   Keyes Elstein, Lynette ^a   Soppe, Carol L ^c   Nepom, Gerald T ^d   Ehlers, Mario R ^c  

^a RHO INC   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Immune Tolerance Network   (United States)

^d BENAROYA RESEARCH INSTITUTE   (United States)

^e Translational Medicine Immunology Development Janssen R and D Pharmaceutical Companies of Johnson and Johnson   (United States)

Author keywords

alefacept; glycemic control; hypoglycemia; immune intervention; islet function; new onset T1d

Indexed keywords

ALEFACEPT; C PEPTIDE; HEMOGLOBIN A1C; INSULIN; PLACEBO; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HYBRID PROTEIN;

ADULT; ARTICLE; BLOOD GLUCOSE METER; CLINICAL ARTICLE; GLYCEMIC CONTROL; HORMONE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRESERVATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; ADOLESCENT; ANALYSIS; BIOSYNTHESIS; CHILD; CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 1; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; MALE; METABOLISM; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADOLESCENT; ADULT; BLOOD GLUCOSE; C-PEPTIDE; CHILD; DIABETES MELLITUS, TYPE 1; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; IMMUNE TOLERANCE; INSULIN; MALE; RECOMBINANT FUSION PROTEINS; YOUNG ADULT;

EID: 84975260052     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2016.04.032     Document Type: Article

References (48)

1. J.L. Chiang, M.S. Kirkman, L.M. Laffel, and A.L. Peters Type 1 Diabetes Sourcebook A. Type 1 diabetes through the life span: a position statement of the American Diabetes Association Diabetes Care 37 2014 2034 2054
2. M.A. Atkinson, G.S. Eisenbarth, and A.W. Michels Type 1 diabetes Lancet 383 2014 69 82
3. M. Lind, A.M. Svensson, M. Kosiborod, and et al. Glycemic control and excess mortality in type 1 diabetes N Engl J Med 371 2014 1972 1982
4. M. Palta, T. LeCaire, K. Daniels, and et al. Risk factors for hospitalization in a cohort with type 1 diabetes. Wisconsin Diabetes Registry Am J Epidemiol 146 1997 627 636
5. A. Icks, J. Rosenbauer, B. Haastert, and G. Giani Hospitalization among diabetic children and adolescents and non-diabetic control subjects: a prospective population-based study Diabetologia 44 Suppl 3 2001 B87 B92
6. C.L. Estrada, K.K. Danielson, M.L. Drum, and R.B. Lipton Hospitalization subsequent to diagnosis in young patients with diabetes in Chicago, Illinois Pediatrics 124 2009 926 934
7. A. Sayers, D. Thayer, J.N. Harvey, and et al. Evidence for a persistent, major excess in all cause admissions to hospital in children with type-1 diabetes: results from a large Welsh national matched community cohort study BMJ Open 5 2015 e005644
8. B.O. Asvold, T. Sand, K. Hestad, and M.R. Bjorgaas Cognitive function in type 1 diabetic adults with early exposure to severe hypoglycemia: a 16-year follow-up study Diabetes Care 33 2010 1945 1947
9. M.R. Bjorgaas Cerebral effects of severe hypoglycemia in young people with type 1 diabetes Pediatr Diabetes 13 2012 100 107
10. N. Mauras, P. Mazaika, B. Buckingham, and et al. Longitudinal assessment of neuroanatomical and cognitive differences in young children with type 1 diabetes: association with hyperglycemia Diabetes 64 2015 1770 1779
11. A. Lin, E.A. Northam, G.A. Werther, and F.J. Cameron Risk factors for decline in IQ in youth with type 1 diabetes over the 12 years from diagnosis/illness onset Diabetes Care 38 2015 236 242
12. A.M. Secrest, D.J. Becker, S.F. Kelsey, and et al. Characterizing sudden death and dead-in-bed syndrome in Type 1 diabetes: analysis from two childhood-onset Type 1 diabetes registries Diabet Med 28 2011 293 300
13. A.L. Clark, C.J. Best, and S.J. Fisher Even silent hypoglycemia induces cardiac arrhythmias Diabetes 63 2014 1457 1459
14. I. Steineck, J. Cederholm, B. Eliasson, and et al. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18,168 people with type 1 diabetes: observational study BMJ 350 2015 h3234
15. Origin Trial Investigators Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial Eur Heart J 34 2013 3137 3144
16. T.W. Lung, D. Petrie, W.H. Herman, and et al. Severe hypoglycemia and mortality after cardiovascular events for type 1 diabetic patients in Sweden Diabetes Care 37 2014 2974 2981
17. Diabetes Control and Complications Trial Research Group Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial Ann Intern Med 128 1998 517 523
18. J.M. Lachin, P. McGee, J.P. Palmer DCCT/EDIC Research Group Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial Diabetes 63 2014 739 748
19. W.M. Kuhtreiber, S.L. Washer, E. Hsu, and et al. Low levels of C-peptide have clinical significance for established type 1 diabetes Diabet Med 32 2015 1346 1353
20. M.W. Steffes, S. Sibley, M. Jackson, and W. Thomas Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial Diabetes Care 26 2003 832 836
21. D.K. Wherrett, J.L. Chiang, A.M. Delamater, and et al. Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report Diabetes Care 38 2015 1975 1985
22. F.B. Barton, M.R. Rickels, R. Alejandro, and et al. Improvement in outcomes of clinical islet transplantation: 1999-2010 Diabetes Care 35 2012 1436 1445
23. M.C. Vantyghem, V. Raverdy, A.S. Balavoine, and et al. Continuous glucose monitoring after islet transplantation in type 1 diabetes: an excellent graft function (beta-score greater than 7) Is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (beta-score greater than 3) J Clin Endocrinol Metab 97 2012 E2078 E2083
24. S. Lablanche, S. Borot, A. Wojtusciszyn, and et al. Five-year metabolic, functional, and safety results of patients with type 1 diabetes transplanted with allogenic islets within the Swiss-French GRAGIL Network Diabetes Care 38 2015 1714 1722
25. M.D. Pescovitz, C.J. Greenbaum, H. Krause-Steinrauf, and et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function N Engl J Med 361 2009 2143 2152
26. T. Orban, B. Bundy, D.J. Becker, and et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial Lancet 378 2011 412 419
27. K.C. Herold, S.E. Gitelman, M.R. Ehlers, and et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders Diabetes 62 2013 3766 3774
28. M.R. Rigby, L.A. DiMeglio, M.S. Rendell, and et al. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial Lancet Diabetes Endocrinol 1 2013 284 294
29. M.R. Rigby, K.M. Harris, A. Pinckney, and et al. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients J Clin Invest 125 2015 3285 3296
30. H.B. Mortensen, P. Hougaard, P. Swift, and et al. New definition for the partial remission period in children and adolescents with type 1 diabetes Diabetes Care 32 2009 1384 1390
31. M.R. Ehlers Immune interventions to preserve β cell function in type 1 diabetes Journal of Investigative Medicine 64 2016 7 13
32. A.K. Davis, S.N. DuBose, M.J. Haller, and et al. Prevalence of detectable C-peptide according to age at diagnosis and duration of type 1 diabetes Diabetes Care 38 2015 476 481
33. X. Dai, J. Zhan, T.A. Demmy, and et al. Monocytes play different roles in stimulating T cells in obese diabetic individuals Int J Immunopathol Pharmacol 28 2015 374 383
34. O. Schultz, F. Oberhauser, J. Saech, and et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases PLoS One 5 2010 e14328
35. M. Koulmanda, M. Bhasin, Z. Awdeh, and et al. The role of TNF-alpha in mice with type 1- and 2- diabetes PLoS One 7 2012 e33254
36. E. Bianchi, G. Ripandelli, S. Taurone, and et al. Age and diabetes related changes of the retinal capillaries: An ultrastructural and immunohistochemical study Int J Immunopathol Pharmacol 29 2016 40 53
37. C.N. Ellis, G.G. Krueger Alefacept Clinical Study Group Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes N Engl J Med 345 2001 248 255
38. J.S. Sorensen, J. Johannesen, F. Pociot, and et al. Residual beta-cell function 3-6 years after onset of type 1 diabetes reduces risk of severe hypoglycemia in children and adolescents Diabetes Care 36 2013 3454 3459
39. G. Freckmann, S. Hagenlocher, A. Baumstark, and et al. Continuous glucose profiles in healthy subjects under everyday life conditions and after different meals J Diabetes Sci Technol 1 2007 695 703
40. D. Xing, C. Kollman, R.W. Beck, and et al. Optimal sampling intervals to assess long-term glycemic control using continuous glucose monitoring Diabetes Technol Ther 13 2011 351 358
41. B.E. Klein, and R. Klein Further insight on the limits of success of glycemic control in type 1 diabetes Diabetes 64 2015 341 343
42. C. Farrington The artificial pancreas: challenges and opportunities Lancet Diabetes Endocrinol 3 2015 937
43. H. Thabit, M. Tauschmann, J.M. Allen, and et al. Home use of an artificial beta cell in type 1 diabetes N Engl J Med 373 2015 2129 2140
44. M. Tauschmann, J.M. Allen, M.E. Wilinska, and et al. Day-and-night hybrid closed-loop insulin delivery in adolescents with type 1 diabetes: a free-living, randomized clinical trial Diabetes Care 2016
45. J.R. Wood, K.M. Miller, D.M. Maahs, and et al. Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines Diabetes Care 36 2013 2035 2037
46. N. Scheinfeld Alefacept: its safety profile, off-label uses, and potential as part of combination therapies for psoriasis J Dermatolog Treat 18 2007 197 208
47. B. Goffe, K. Papp, D. Gratton, and et al. An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy Clin Ther 27 2005 1912 1921
48. M. Lorenzin, A. Ortolan, M. de Hooge, and et al. Lengthening the time intervals between doses of biological agents in psoriatic arthritis patients: A single-center retrospective study Int J Immunopathol Pharmacol 28 2015 479 487